Next-Gen ADCs: Araris CEO Highlights Potential In Linker Technology
Executive Summary
In Vivo sat down with 2023 Rising Leader Philipp Spycher, CEO of Araris Biotech, to discuss trends in antibody-drug conjugate R&D, and how Araris hopes to disrupt today’s chemotherapy treatment paradigm with novel linker technology.
You may also be interested in...
Exploring Alltrna’s Rare Disease Platform
Michelle Werner, CEO of Alltrna, sat down with In Vivo to discuss rare disease as an increasingly important area of study, innovation in the space and how the emerging biotech hopes to impact the treatment landscape.